Drug Profile
ProScan A
Latest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Progenics Pharmaceuticals
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 21 Jan 2002 Discontinued - Phase-I for HIV infections (diagnosis) in USA (unspecified route)
- 21 Oct 1999 No development reported - Phase-I for HIV infections (diagnosis) in USA (unspecified route)